| 李武德,胡思琪,贺胜焜,刘美玲,陈立谋,邓蜀湘,曹梦悦,奉水东.EGFR突变与肺癌手术患者预后关系的Meta分析.[J].中南医学科学杂志.,2021,(4):418-422. |
| EGFR突变与肺癌手术患者预后关系的Meta分析 |
| A Meta analysis of the correlation between EGFR mutation and prognosis of surgical patients with lung cancer |
| 投稿时间：2021-02-28 修订日期：2021-03-30 |
| DOI：10.15972/j.cnki.43-1509/r.2021.04.011 |
| 中文关键词: 表皮生长因子受体 突变 肺癌 预后 Meta分析 |
| 英文关键词:EGFR mutation lung cancer prognosis Meta analysis |
| 基金项目:湖南省自然科学基金项目(2018JJ2342) |
| 作者 | 单位 | E-mail | | 李武德 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | e-mail为lwd123zll@163.com,e-mail为shuidong_f@hotmail.com | | 胡思琪 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | | | 贺胜焜 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | | | 刘美玲 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | | | 陈立谋 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | | | 邓蜀湘 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | | | 曹梦悦 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | | | 奉水东 | 南华大学公共卫生学院, 湖南省衡阳市 421001 | e-mail为lwd123zll@163.com,e-mail为shuidong_f@hotmail.com |
|
| 摘要点击次数: 405 |
| 全文下载次数: 299 |
| 中文摘要: |
| 目的Meta分析系统评价肺癌手术患者表皮生长因子受体(EGFR)突变与肺癌预后的相关性。方法计算机检索PubMed、Web of Science、Cochrane图书馆、EMBASE、CNKI和万方数据库,搜集有关EGFR突变与肺癌手术患者预后相关性的文献,检索时限均从建库至2020年11月。对纳入研究进行偏倚风险评价后,采用Stata12.0软件对肺癌患者EGFR突变组与无突变组的无病生存期(DFS)和总生存期(OS)进行Meta分析。结果共纳入15个随访队列,共3 386例肺癌患者,其中有EGFR突变1 096例,无EGFR突变2 290例。Meta分析结果显示,与无突变者比较,有EGFR突变者OS更长(HR＝0.71,95%CI 0.54~0.950,P＝0.021),而DFS差异无显著性(HR＝1,95%CI 0.66~1.50,P＝0.992)。TNM分期在Ⅰ期以上的合并效应值异质性明显降低(I2＝0,P＝0.067),EGFR突变者不同病理分期的DFS差异无显著性(P＞0.05)。敏感性分析显示,逐一去除文献前后合并效应值无明显变化,Begg检验分析显示不存在发表偏倚(P＞0.05)。结论EGFR突变可能与肺癌手术患者OS相关,但与DFS不相关。 |
| 英文摘要: |
| To systematically evaluate the correlation between epidermal growth factor receptor (EGFR) mutations and the prognosis of lung cancer in patients undergoing lung cancer surgery. MethodsThe study searched PubMed, Web of Science, CochraneLibrary, EMBASE, CNKI and Wanfang databases to collect research on the correlation between EGFR mutations and the prognosis of patients undergoing lung cancer surgery. The search time limit is from the establishment of the database to November 2020. Assessed the risk of bias in the included studies, Meta-analysis of the disease-free survival (DFS) and overall survival of the EGFR mutation group and the mutation-free group of lung cancer patients was performed using Stata12.0 software (OS). ResultsA total of 15 follow-up cohorts were included, with a total of 3 386 lung cancer patients, including 1 096 cases with EGFR mutations and 2 290 cases without EGFR mutations.The results of Meta analysis showed that those with EGFR mutations had longer OS than those without mutations(HR＝0.71,95%CI 0.54－0.950, P＝0.021). There is no statistically significant difference in DFS relative to those without mutations(HR＝1,95%CI 0.66－1.50, P＝0.992). The combined effect value heterogeneity of TNM staging above stage I was significantly reduced (I2＝0, P＝0.067), and there was no significant difference in DFS between different pathological stages of EGFR mutations (P＞0.05).Sensitivity analysis showed that the combined effect size did not change significantly before and after the literature was removed one by one, the included literature has no publication bias (P＞0.05). ConclusionsEGFR mutations are related to the OS of patients undergoing lung cancer surgery, but not to DFS. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|